JY
TXG icon

Jeff Yass’s 10x Genomics TXG Stock Holding History

Jeff Yass’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.58M Sell
249,800
-21,400
-8% -$561K ﹤0.01% 3480
2026
Q1 		$5.76M Buy
271,200
+169,400
+166% +$3.39M ﹤0.01% 3992
2025
Q4 		$1.66M Sell
101,800
-29,000
-22% -$438K ﹤0.01% 6033
2025
Q3 		$1.53M Buy
130,800
+73,400
+128% +$957K ﹤0.01% 6378
2025
Q2 		$665K Buy
57,400
+44,700
+352% +$407K ﹤0.01% 8501
2025
Q1 		$111K Sell
12,700
-6,500
-34% -$81.9K ﹤0.01% 11472
2024
Q4 		$276K Sell
19,200
-13,700
-42% -$216K ﹤0.01% 10019
2024
Q3 		$743K Sell
32,900
-34,100
-51% -$705K ﹤0.01% 7514
2024
Q2 		$1.3M Sell
67,000
-38,800
-37% -$1.02M ﹤0.01% 5974
2024
Q1 		$3.97M Buy
105,800
+60,100
+132% +$2.64M ﹤0.01% 4030
2023
Q4 		$2.56M Sell
45,700
-30,600
-40% -$1.33M ﹤0.01% 4862
2023
Q3 		$3.15M Buy
76,300
+1,300
+2% +$67.6K ﹤0.01% 4293
2023
Q2 		$4.19M Sell
75,000
-117,800
-61% -$6.38M ﹤0.01% 3812
2023
Q1 		$10.8M Buy
192,800
+126,000
+189% +$5.88M ﹤0.01% 2345
2022
Q4 		$2.43M Sell
66,800
-10,700
-14% -$350K ﹤0.01% 4364
2022
Q3 		$2.21M Sell
77,500
-20,700
-21% -$789K ﹤0.01% 4710
2022
Q2 		$4.44M Buy
98,200
+60,700
+162% +$3.15M ﹤0.01% 3381
2022
Q1 		$2.85M Sell
37,500
-4,400
-11% -$385K ﹤0.01% 4716
2021
Q4 		$6.24M Sell
41,900
-31,500
-43% -$4.82M ﹤0.01% 3383
2021
Q3 		$10.7M Sell
73,400
-82,200
-53% -$14.1M ﹤0.01% 2767
2021
Q2 		$30.5M Buy
155,600
+60,500
+64% +$10.9M ﹤0.01% 1588
2021
Q1 		$17.2M Buy
95,100
+70,600
+288% +$12.2M ﹤0.01% 2052
2020
Q4 		$3.47M Sell
24,500
-55,600
-69% -$8.07M ﹤0.01% 4059
2020
Q3 		$9.99M Sell
80,100
-29,100
-27% -$3.05M ﹤0.01% 2178
2020
Q2 		$9.75M Buy
109,200
+57,200
+110% +$4.46M ﹤0.01% 2165
2020
Q1 		$3.24M Buy
52,000
+16,300
+46% +$1.27M ﹤0.01% 3165
2019
Q4 		$2.72M Buy
+35,700
New +$2.15M ﹤0.01% 3845

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jeff Yass's TXG Position: Q2 2026 in Review

Jeff Yass reduced its 10x Genomics (TXG) stake by 43% in Q2 2026, selling an estimated $1.69M and leaving 86,421 shares worth $3.31M. The position accounts for ﹤0.01% of the portfolio, ranked #5420.

Jeff Yass first reported a position in TXG in Q3 2019 and has held it in 24 quarters since. The position peaked at $8.45M in Q1 2025. 389 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Jeff Yass held 86,421 shares of 10x Genomics worth $3.31M as of Q2 2026.
  • Jeff Yass sold 64,559 10x Genomics shares in Q2 2026, an estimated $1.69M.
  • 10x Genomics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #5420 holding.
  • Jeff Yass first reported a position in 10x Genomics in Q3 2019 and has held it in 24 quarters since.
  • Jeff Yass's 10x Genomics position peaked at $8.45M in Q1 2025.
  • 389 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.